[
  {
    "ts": null,
    "headline": "Top Research Reports for Eli Lilly, Netflix & GE Aerospace",
    "summary": "LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs.",
    "url": "https://finnhub.io/api/news?id=58b6aac6ca314dd0b51883447506ef092542ecc44a514862f7843700de8d81e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752525300,
      "headline": "Top Research Reports for Eli Lilly, Netflix & GE Aerospace",
      "id": 135931649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs.",
      "url": "https://finnhub.io/api/news?id=58b6aac6ca314dd0b51883447506ef092542ecc44a514862f7843700de8d81e9"
    }
  },
  {
    "ts": null,
    "headline": "Illimis secures funding for GAIA-based Alzheimer’s therapeutics",
    "summary": "The company plans to utilise the funds to extend its research into immune disorders.",
    "url": "https://finnhub.io/api/news?id=659e936c8bedf23240b351c85e7aa83d42bccce5fb3ab233d15f27269f463961",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752506578,
      "headline": "Illimis secures funding for GAIA-based Alzheimer’s therapeutics",
      "id": 135934204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company plans to utilise the funds to extend its research into immune disorders.",
      "url": "https://finnhub.io/api/news?id=659e936c8bedf23240b351c85e7aa83d42bccce5fb3ab233d15f27269f463961"
    }
  },
  {
    "ts": null,
    "headline": "WW International: Menopause Health's Comeback",
    "summary": "WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis of WW stock now.",
    "url": "https://finnhub.io/api/news?id=bb97a59c0c40d59ede7db26534a002c84e3aaccbf3590b11b618c7fb0703d86c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752505172,
      "headline": "WW International: Menopause Health's Comeback",
      "id": 135930279,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202833743/image_1202833743.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis of WW stock now.",
      "url": "https://finnhub.io/api/news?id=bb97a59c0c40d59ede7db26534a002c84e3aaccbf3590b11b618c7fb0703d86c"
    }
  },
  {
    "ts": null,
    "headline": "MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?",
    "summary": "Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.",
    "url": "https://finnhub.io/api/news?id=5ed0b77d6dc0a36658d38ba6207ff63d9f666a1de0898608b6a6d180ab9cc564",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752502980,
      "headline": "MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?",
      "id": 135934205,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.",
      "url": "https://finnhub.io/api/news?id=5ed0b77d6dc0a36658d38ba6207ff63d9f666a1de0898608b6a6d180ab9cc564"
    }
  },
  {
    "ts": null,
    "headline": "ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?",
    "summary": "As ProKidney hits a fresh 52-week high, can it sustain momentum through late-stage trials, or should investors stay cautious amid the market’s mixed view?",
    "url": "https://finnhub.io/api/news?id=6ca13cd68f8220dd4357c2a93345c943c747720ae613712cda63f8c900c22b36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752500702,
      "headline": "ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?",
      "id": 135927469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As ProKidney hits a fresh 52-week high, can it sustain momentum through late-stage trials, or should investors stay cautious amid the market’s mixed view?",
      "url": "https://finnhub.io/api/news?id=6ca13cd68f8220dd4357c2a93345c943c747720ae613712cda63f8c900c22b36"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=bf329dc58e449d9b8210b6b7d9c778bbae3bd3dc9e0bfe194f72652dc590cba2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752498004,
      "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
      "id": 135927470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=bf329dc58e449d9b8210b6b7d9c778bbae3bd3dc9e0bfe194f72652dc590cba2"
    }
  },
  {
    "ts": null,
    "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
    "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752490011,
      "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
      "id": 135926879,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192786673/image_2192786673.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05"
    }
  },
  {
    "ts": null,
    "headline": "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research Report 2025 | Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements",
    "summary": "The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like P",
    "url": "https://finnhub.io/api/news?id=01058650ccd72bef4d66fdf57aa8a5d3248643ea3ea5f5a8ec1d0fc4de9e122c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752487440,
      "headline": "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research Report 2025 | Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements",
      "id": 135923046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like P",
      "url": "https://finnhub.io/api/news?id=01058650ccd72bef4d66fdf57aa8a5d3248643ea3ea5f5a8ec1d0fc4de9e122c"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1 Agonists Drug Pipeline Analysis Market Report 2025 | Next-generation GLP-1 Agonists Pave the Way for Diabetes and Obesity Management",
    "summary": "Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss benefits. Key players such as Eli Lilly innovate, contributing to market expansion and investment in metabolic health.Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The \"GLP-1 Agonists Drug Pipeline Analysis Report 2025\" drug pipelines has been added to ResearchAndMarkets.com's offering.The GLP-1 Agonists",
    "url": "https://finnhub.io/api/news?id=95aa4007db5aa1240f6bd4bfa2e3d5bbdcf9d73a2147c7851317e69a717d05d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752486960,
      "headline": "GLP-1 Agonists Drug Pipeline Analysis Market Report 2025 | Next-generation GLP-1 Agonists Pave the Way for Diabetes and Obesity Management",
      "id": 135921009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss benefits. Key players such as Eli Lilly innovate, contributing to market expansion and investment in metabolic health.Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The \"GLP-1 Agonists Drug Pipeline Analysis Report 2025\" drug pipelines has been added to ResearchAndMarkets.com's offering.The GLP-1 Agonists",
      "url": "https://finnhub.io/api/news?id=95aa4007db5aa1240f6bd4bfa2e3d5bbdcf9d73a2147c7851317e69a717d05d7"
    }
  },
  {
    "ts": null,
    "headline": "Obesity Drug Pipeline Analysis Report 2025 | Pfizer and Eli Lilly Lead the Charge in Cutting-Edge Obesity Research",
    "summary": "In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical support bolstering development. The 2025 Obesity Drug Pipeline Report offers insights into recent breakthroughs, clinical trials, and regulatory trends, highlighting the shift toward personalized therapies and novel drug classes like peptides and RNA-based treatments. Key players include Pfizer and Eli L",
    "url": "https://finnhub.io/api/news?id=bf831dc0f077513f8d51e1e3b36151a67ad12aa03ca98defb9b11525ad47eca5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752486360,
      "headline": "Obesity Drug Pipeline Analysis Report 2025 | Pfizer and Eli Lilly Lead the Charge in Cutting-Edge Obesity Research",
      "id": 135920859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical support bolstering development. The 2025 Obesity Drug Pipeline Report offers insights into recent breakthroughs, clinical trials, and regulatory trends, highlighting the shift toward personalized therapies and novel drug classes like peptides and RNA-based treatments. Key players include Pfizer and Eli L",
      "url": "https://finnhub.io/api/news?id=bf831dc0f077513f8d51e1e3b36151a67ad12aa03ca98defb9b11525ad47eca5"
    }
  },
  {
    "ts": null,
    "headline": "IYH: An Aggressive Positioning On The U.S. Healthcare Industry",
    "summary": "IYH: An Aggressive Positioning On The U.S. Healthcare Industry",
    "url": "https://finnhub.io/api/news?id=340f45607bb5065e194dbc14f156d63272ffd4058d421fa9dc9e738b185f06ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752486295,
      "headline": "IYH: An Aggressive Positioning On The U.S. Healthcare Industry",
      "id": 135925479,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=340f45607bb5065e194dbc14f156d63272ffd4058d421fa9dc9e738b185f06ca"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
    "summary": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
    "url": "https://finnhub.io/api/news?id=af2aafb0cf42b97bac23331ec68d797ee9e274d8927b39712211af92d4fdb47c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752483060,
      "headline": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
      "id": 135948893,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
      "url": "https://finnhub.io/api/news?id=af2aafb0cf42b97bac23331ec68d797ee9e274d8927b39712211af92d4fdb47c"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Ready to Rebound. 3 to Watch Now.",
    "summary": "Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.  Large pharmaceutical companies, facing thinning pipelines, are aggressively acquiring cutting-edge biotech firms.  Notable billion-dollar deals in the past two months include the acquisition of  Verona Pharma  by Merck,  Sanofi’s   buyout of  Blueprint Medicines  and  Eli Lilly’s   purchase of  Verve Therapeutics  In a significant technical move, the ETF has recently broken out above an eight-month trend of lower highs—an important shift dating back to the start of the current administration.",
    "url": "https://finnhub.io/api/news?id=d921a7ea8f49b289f453f7c87799f0b573d2ce2df7c042968a8fea9c39cf3e8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752471000,
      "headline": "Biotech Stocks Are Ready to Rebound. 3 to Watch Now.",
      "id": 135917250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.  Large pharmaceutical companies, facing thinning pipelines, are aggressively acquiring cutting-edge biotech firms.  Notable billion-dollar deals in the past two months include the acquisition of  Verona Pharma  by Merck,  Sanofi’s   buyout of  Blueprint Medicines  and  Eli Lilly’s   purchase of  Verve Therapeutics  In a significant technical move, the ETF has recently broken out above an eight-month trend of lower highs—an important shift dating back to the start of the current administration.",
      "url": "https://finnhub.io/api/news?id=d921a7ea8f49b289f453f7c87799f0b573d2ce2df7c042968a8fea9c39cf3e8d"
    }
  }
]